A strong performance by AMG510 stokes fresh enthusiasm on the future of Amgen's landmark KRAS G12C program — but shares slide
In the run-up to today’s announcement from Amgen on the latest update to come out of their development effort on AMGN510, Amgen R&D chief Dave Reese was well aware of the intense anticipation building up.
“I’ve never seen this kind of interest in a Phase I,” he says, and that’s saying something for someone who’s an oncologist by background.
Reese’s bottom line going into the presentation Sunday in Barcelona at the World Conference on Lung Cancer: “We remain incredibly enthusiastic.”
For good reason.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 83,000+ biopharma pros reading Endpoints daily — and it's free.